Search

Tilactase

[A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] … [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.

Tenecteplase

It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids … 296-299 in the protease domain.

Cilostazol

It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. … Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia

Desloratadine

Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. … Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

Ceftriaxone

Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].

Etomidate

Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.

Cromoglicic acid

It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. … A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.

Amisulpride

In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of … As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and

Frangula purshiana bark

Adalimumab

[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_. … 2023 [L49101] and adalimumab-ryvk - which was approved in February 2024[L52088].